VEGFA and neoplasm: High VEGF levels in the tumor milieu are a known barrier to immunotherapy [42, 43, 44], and the ability of ISOQ/ZAF treatment to reduce VEGF suggests a more normalized vasculature and improved immune access to the tumor.